News Article November 25, 2024

November 25, 2024

Perioperative Vorasidenib and Ivosidenib Remain Effective, Safe in IDH1+ Diffuse Glioma

Ashling Wahner

Fact checked by:Chris Ryan

Conference|Society for Neuro-Oncology Annual Meeting

Perioperative vorasidenib or ivosidenib demonstrated sustained clinical benefit in patients with predominantly non-enhancing IDH1-mutant diffuse

Vorasidenib (Voranigo) or ivosidenib (Tibsovo) administered before and after surgery demonstrated sustained clinical benefit in patients with predominantly non-enhancing IDH1-mutant diffuse glioma, according to updated findings from a phase 1 trial (NCT03343197) presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting.

At a data cutoff date of September 23, 2023, 64% of evaluable patients who received vorasidenib (n = 22) and 45.4% of evaluable patients who received ivosidenib experienced tumor reduction. The overall response rate (ORR) among evaluable patients who received vorasidenib (n = 22) was 45.5%, including partial response (PR), minor response (MR), stable disease (SD), and progressive disease (PD) rates of 18.2%, 27.3%, 36.4%, and 18.2%, respectively. The median time to response in this arm was 9.2 months (range, 2-20), and the median duration of response (DOR) was not evaluable (NE; range, 14.7 months-NE). The median duration of treatment was 44.67 months .(range, 0.9-62.7)

The ORR among evaluable patients who received ivosidenib (n = 22) was 31.8%, including PR, MR, SD, and PD rates of 22.7%, 9.1%, 59.1%, and 9.1%, respectively. The median time to response in this arm was 5.6 months (range, 2-13), and the median DOR was 42.4 months (range, 1.8-NE). The median duration of treatment was 23.92 months (range, 0.0-62.7).

“With additional [follow-up of approximately] 3.5 years from previously published results, vorasidenib and ivosidenib continue to show clinical benefit immediately after surgery in patients with predominantly non-enhancing glioma,” presenting author Timothy F. Cloughesy, MD, and coauthors wrote in a presentation of the data. “Vorasidenib resulted in durable disease control including objective responses, consistent with phase 3 INDIGO study [NCT04164901] results.”

Cloughesy is a professor and director in the Department of Neurology, Neurological Services, and the Neuro-Oncology Program, as well as a physician in the Department of Neurology and a member of the Brain Research Institute at the UCLA Health Jonsson Comprehensive Cancer Center in Los Angeles, California

27 November 2024

دیدگاه خود را بنویسید

  • {{value}}
این دیدگاه به عنوان پاسخ شما به دیدگاهی دیگر ارسال خواهد شد. برای صرف نظر از ارسال این پاسخ، بر روی گزینه‌ی انصراف کلیک کنید.
دیدگاه خود را بنویسید.
کمی صبر کنید...
درباره‌ی نویسنده
لورم ایپسوم متن ساختگی با تولید سادگی نامفهوم از صنعت چاپ و با استفاده از طراحان گرافیک است. چاپگرها و متون بلکه روزنامه و مجله در ستون و سطرآنچنان که لازم است و برای شرایط فعلی تکنولوژی مورد نیاز و کاربردهای متنوع با هدف بهبود ابزارهای کاربردی می باشد.
اطلاعات بیش‌تر
دسته‌بندی
عضویت خبرنامه
عضو خبرنامه ماهانه وب‌سایت شوید و تازه‌ترین نوشته‌ها را در پست الکترونیک خود دریافت کنید.
آدرس پست الکترونیک خود را بنویسید.
کمی صبر کنید...
برچسب‌ها
موردی وجود ندارد.